Comparing Vericel (NASDAQ:VCEL) & InflaRx (NASDAQ:IFRX)

InflaRx (NASDAQ:IFRX – Get Free Report) and Vericel (NASDAQ:VCEL – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Risk & Volatility

InflaRx has a beta of 2.38, indicating that its share price is 138% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Insider & Institutional Ownership

42.4% of InflaRx shares are owned by institutional investors. 16.3% of InflaRx shares are owned by insiders. Comparatively, 7.6% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares InflaRx and Vericel’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
InflaRx N/A -32.04% -27.33%
Vericel 10.27% 9.09% 6.68%

Earnings and Valuation

This table compares InflaRx and Vericel”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
InflaRx -$33,931.00 -4,516.89 -$51.63 million ($0.39) -2.67
Vericel $276.26 million 10.62 $16.52 million $0.64 89.88

Vericel has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for InflaRx and Vericel, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InflaRx 1 2 5 1 2.67
Vericel 0 2 5 1 2.88

InflaRx currently has a consensus target price of $7.43, suggesting a potential upside of 614.29%. Vericel has a consensus target price of $62.00, suggesting a potential upside of 7.79%. Given InflaRx’s higher possible upside, equities analysts clearly believe InflaRx is more favorable than Vericel.

Summary

Vericel beats InflaRx on 9 of the 13 factors compared between the two stocks.

About InflaRx

(Get Free Report)

InflaRx N.V. is a biotechnology company that develops therapies for inflammatory and autoimmune diseases. Its research focuses on the complement system, a part of the immune system that can contribute to inflammation and tissue damage. The company’s lead antibody, vilobelimab, targets the complement protein C5a. In 2023, the U.S. Food and Drug Administration granted emergency use authorization for vilobelimab, marketed as Gohibic, for certain hospitalized adults with COVID-19. InflaRx is also investigating the drug in other inflammatory conditions.

About Vericel

(Get Free Report)

Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.

Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.